| Volume: | 2,019,931 |
|---|---|
| Day's Low: | $39.10 |
| 52-wk Low: | $26.01 |
| Previous Close: | $39.51 |
| Dividend: | $0.00 |
| Market Cap: | NA |
| Avg Volume: | NA |
|---|---|
| Day's High: | $39.54 |
| 52-wk High: | $42.08 |
| Open Price: | $39.30 |
| Yield: | 0.00% |
| P/E (Forward): | NA |
| 8:19 AM | 10/29/2009 | UPDATE: Roche's New Diabetes Drug Works Better Than Byetta |
| 4:48 AM | 10/29/2009 | Roche: New Diabetes Drug Works Better Than Byetta - Study |
| 3:01 AM | 10/29/2009 | Roche: Taspoglutide Meets Endpoint In Type 2 Diabetes Trials |
| 3:57 PM | 10/28/2009 | UPDATE:Senator:Medicare To Reverse Avastin Reimbursement Decision |
| 3:57 PM | 10/28/2009 | CORRECT:UPDATE:Senator:Medicare To Reverse Avastin Reimbursement Decision |
| 12:53 PM | 10/28/2009 | Sen Kohl:Medicare To Reverse Reimbursement Decision On Avastin |
| 12:44 PM | 10/28/2009 | Human Genome Looks To Confirm Lupus Success With 2nd Trial |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | NA | NA | NA |
| EPS, GAAP | NA | NA | NA |
| Consensus Estimate | NA | NA | NA |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | NA | NA | NA |
| EPS, GAAP | NA | NA | NA |
| Consensus Estimate | NA | NA | NA |
| RHHBY | Industry Average | |
| P/E (TTM) | NA | NA |
| P/E (Forward) | NA | NA |
| PEG Ratio | NA | NA |
| Price/Sales | NA | NA |
| Beta | NA | NA |